Metotrexato Semanal Cipla

Methotrexate, the active ingredient in Metotrexato Semanal Cipla, is a folate antagonist antimetabolite presented as an oral tablet for weekly use. It is employed to modify disease progression in autoimmune disorders and certain malignancies. The medication belongs to the disease-modifying antirheumatic drug (DMARD) class and is indicated for conditions such as rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, and non‑Hodgkin lymphoma.

GNH USA supplies Metotrexato Semanal Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is used in several disease categories where it interferes with abnormal cell proliferation and immune activation. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and decreases disease severity. - Acute lymphoblastic leukemia: inhibits malignant lymphoblast proliferation as part of chemotherapy regimens. - Non‑Hodgkin lymphoma: contributes to tumor control in combination therapy.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mouth sores or oral ulceration - Diarrhea or abdominal discomfort - Elevated liver enzymes

Serious or Rare Side Effects: - Bone marrow suppression leading to anemia or infection - Severe liver toxicity or fibrosis - Pulmonary toxicity, including interstitial pneumonitis - Renal impairment or failure - Rare skin reactions such as Stevens‑Johnson syndrome

When prescribing methotrexate, clinicians should observe several safety measures to minimize risks. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Check blood counts: regular complete blood count to detect marrow suppression. - Avoid alcohol: limit intake to reduce hepatic toxicity. - Use folic acid supplementation: prescribe folic acid to lessen mucosal and hematologic side effects. - Contraindicated in pregnancy: do not use in women who are pregnant or may become pregnant. - Store below 25°C: keep tablets in the original container, protect from moisture and heat.

Methotrexate interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal and renal toxicity. - Penicillins and other antibiotics: may enhance bone marrow suppression. - Live vaccines: immunosuppression can lead to severe infection.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate clearance. - Sulfonamide antibiotics: can increase plasma levels of methotrexate. - Vitamin supplements containing folic acid (high dose): may reduce therapeutic efficacy. - Anticonvulsants (e.g., phenytoin): may lower methotrexate concentrations.